Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals.
Metformin improves insulin sensitivity , which is correlated to phospholipid fatty acid composition in obese type 2 diabetics . We aim ed at investigating the relationship between Metformin and fatty acids in obese insulin resistant non-diabetic individuals . A double-blind , placebo-controlled 20-week trial was performed in 21 BMI and age-matched insulin resistant non-diabetic individuals receiving either Metformin or placebo .  Insulin sensitivity together with metabolic parameters and fatty acids in serum phospholipids were measured at baseline and at 20 weeks . A significant decrease in body weight , BMI , percentage body fat , the sum of saturated fatty acids in serum phospholipids and increase in insulin sensitivity index were observed following the 20-week treatment . These changes did not differ significantly between the groups . Energy restriction rather than Metformin treatment appears to be responsible for the observed changes . The associations previously found in diabetics between insulin sensitivity and phospholipid fatty acids may not be mediated by Metformin
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .